Literature DB >> 7621845

Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.

C M Masimirembwa1, J A Hasler, I Johansson.   

Abstract

The interaction of antiparasitic drugs with the polymorphic cytochrome P450 2D6 was studied in human liver microsomes. Of ten different drugs tested, three quinolines, oxamniquine, primaquine and chloroquine inhibited microsomal CYP2D6-catalysed formation of 1'hydroxybufuralol at concentrations that might have clinical consequences in drug use. These drugs inhibited competitively bufuralol metabolism with Ki values of 22, 23 and 15 microM, respectively, indicative of high affinity for the CYP2D6-active site. The results imply that oxamniquine, primaquine and chloroquine could be substrates of cytochrome P4502 D6 or that they are potent non-substrate inhibitors of the enzyme similar to quinidine. In either case, the inhibition of CYP2D6 by these agents could lead to interference with in vivo population-phenotyping procedures in the tropical regions where treatment with the drugs is common.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621845     DOI: 10.1007/bf00202169

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.

Authors:  R Fonne-Pfister; U A Meyer
Journal:  Biochem Pharmacol       Date:  1988-10-15       Impact factor: 5.858

Review 2.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.

Authors:  G Mikus; H R Ha; S Vozeh; C Zekorn; F Follath; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents.

Authors:  M Murray
Journal:  Drug Metab Rev       Date:  1987       Impact factor: 4.518

Review 5.  Cytochromes P450: their active-site structure and mechanism of oxidation.

Authors:  L Koymans; G M Donné-op den Kelder; J M Koppele Te; N P Vermeulen
Journal:  Drug Metab Rev       Date:  1993       Impact factor: 4.518

6.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.

Authors:  U M Zanger; F Vilbois; J P Hardwick; U A Meyer
Journal:  Biochemistry       Date:  1988-07-26       Impact factor: 3.162

7.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6).

Authors:  L Koymans; N P Vermeulen; S A van Acker; J M te Koppele; J J Heykants; K Lavrijsen; W Meuldermans; G M Donné-Op den Kelder
Journal:  Chem Res Toxicol       Date:  1992 Mar-Apr       Impact factor: 3.739

8.  Pharmacologic actions of 4-aminoquinoline compounds.

Authors:  A H Mackenzie
Journal:  Am J Med       Date:  1983-07-18       Impact factor: 4.965

9.  Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.

Authors:  T Wolff; L M Distlerath; M T Worthington; J D Groopman; G J Hammons; F F Kadlubar; R A Prough; M V Martin; F P Guengerich
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

10.  Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs.

Authors:  D L Lancaster; R A Adio; K K Tai; O O Simooya; G D Broadhead; G T Tucker; M S Lennard
Journal:  J Pharm Pharmacol       Date:  1990-04       Impact factor: 3.765

View more
  14 in total

1.  The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.

Authors:  Tuomas Korhonen; Ari Tolonen; Jouko Uusitalo; Stefan Lundgren; Jorma Jalonen; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 3.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

5.  Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Authors:  C K Yeung; Y Fujioka; H Hachad; R H Levy; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

Review 6.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

7.  Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

Authors:  O O Simooya; G Sijumbil; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

8.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 9.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

10.  Spectrofluorimetric determination of oxamniquine in dosage forms and spiked human plasma through derivatization with 1-dimethylaminonaphthalene-5-sulphonyl chloride.

Authors:  N El-Enany; F Belal; M Rizk
Journal:  J Fluoresc       Date:  2007-12-05       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.